Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$707.33M+556.16%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- August James Troendle
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 6,500
- Beta
- 1.15
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 7.91
Financials
Revenue
$707.33M+556.2%Net Income
$121.36M+2309.9%EBITDA
$133.83M+399.0%Free Cash Flow
$138.10M+245.0%EPS (diluted)
$4.25+3169.2%Shares Outstanding (diluted)
28.76M-23.6%Operating Expenses
$48.10MCash & Debt
$502.69MReturn of Capital
$294.76MRevenue by Segment (annual)
$2.53BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.53B | $451.12M | $15.64 |
| 2024 | $2.11B | $404.39M | $13.06 |
| 2023 | $1.89B | $282.81M | $9.20 |
| 2022 | $1.46B | $245.37M | $7.57 |
| 2021 | $1.14B | $181.85M | $5.06 |
| 2020 | $925.92M | $145.38M | $4.07 |
| 2019 | $860.97M | $100.44M | $2.79 |
| 2018 | $704.59M | $73.19M | $2.05 |
| 2017 | $436.15M | $39.12M | $1.00 |
| 2016 | $421.58M | $13.43M | $0.38 |
| 2015 | $359.06M | $-8.67M | $-0.28 |
| 2014 | $290.04M | $-15.57M | $-0.53 |
| 2013 | $272.89M | $24.84M | $1.33 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MEDP's reported EPS growth of 22.8% a year over 12 years.
- EPS in 5 years
- $43.67
- Implied price
- $1,572
- Return from $599.47
- 21.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $781.65 — today's price is already 23.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 26 | 31 | 36 | 41 | 46 |
|---|---|---|---|---|---|
| 12.8% | 4.4% | 8.1% | 11.4% | 14.3% | 17.0% |
| 17.8% | 9.0% | 12.9% | 16.3% | 19.4% | 22.2% |
| 22.8% | 13.6% | 17.7% | 21.3% | 24.5% | 27.4% |
| 27.8% | 18.3% | 22.5% | 26.2% | 29.5% | 32.5% |
| 32.8% | 22.9% | 27.3% | 31.1% | 34.6% | 37.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+0.37%Social Signal Score
Mentions (9)
- News (Marketaux)gurufocus.com·5d ago·Positive
UBS Initiates Coverage of Medpace (MEDP) with Neutral Rating and $673 Price Target On September 30, 2026, UBS began coverag[+330 characters]
View source ↗ - Newszacks.com·6d ago·Negative
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.
View source ↗ - Newsbusinesswire.com·13d ago·Positive
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026 CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must reg…
View source ↗ - Newszacks.com·14d ago·Positive
Medpace (MEDP) Outperforms Broader Market: What You Need to Know Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day's close.
View source ↗ - 4chan /biz/biz·20d ago·Neutral
>>62692571 I saw that it was pretty funny maybe he can change even if he tries, even if he wants to >HLMN >MEDP
View source ↗ - Newszacks.com·21d ago·Neutral
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note In the latest trading session, Medpace (MEDP) closed at $595.41, marking a +1.34% move from the previous day.
View source ↗ - Newszacks.com·45d ago·Neutral
Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report? Medpace (MEDP) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·48d ago·Neutral
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·56d ago·Positive
Here's Why Medpace (MEDP) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗
Earnings
Wed, Oct 21(in 2 weeks)
Consensus estimate $4.42 per share
Typical surprise +9.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 22$4.25 vs $3.98beat
- Wed, Apr 22$4.28 vs $3.92beat
- Mon, Feb 9$4.67 vs $4.19beat
- Wed, Oct 22$3.86 vs $3.53beat
- Mon, Jul 21$3.10 vs $2.98beat
- Mon, Apr 21$3.67 vs $3.06beat
Estimates and results for MEDP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MEDP officers and directors.
- Bought
- —
- Sold
- $230.3m
0 trades
33 trades
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- David J. Taylorhouse · OH02 · disclosed May 29, 2026 (14d later)Buy$1,001 - $15,000
- David J. Taylorhouse · OH02 · disclosed Mar 9, 2026 (11d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 13, 2026 (29d later)Sell$15,001 - $50,000
- David J. Taylorhouse · OH02 · disclosed Feb 3, 2026 (18d later)Sell$1,001 - $15,000
- David J. Taylorhouse · OH02 · disclosed Feb 3, 2026 (5d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Sell$1,001 - $15,000
- David J. Taylorhouse · OH02 · disclosed Sep 3, 2025 (42d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 15, 2025 (22d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Feb 14, 2025 (32d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 15, 2024 (20d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 15, 2024 (22d later)Sell$1,001 - $15,000
- Michael Guesthouse · MS03 · disclosed Dec 11, 2023 (28d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 29, 2022 (38d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 15, 2021 (20d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 11, 2021 (32d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2021 (30d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 5, 2020 (2d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.